Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 6.0 Contact Hours.
Acknowledgment of Commercial SupportThis activity is supported by educational grants from AbbVie, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Genentech, Lilly, Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
April 8, 2017
18001 Collins Ave
Sunny Isles Beach, FL 33160
OverviewThe Miami Lung Cancer Conference® returns for its 4th year, and will bring updates on the latest advances in current and future approaches for lung cancer treatment. This 1-day meeting will address immunotherapies and targeted agents both approved and in development, treatment for special populations, and a look forward from the experts.
Participants will learn from engaging presentations delivered by thought leaders, reviewing and discussing realistic and complex scenarios, sharing clinical experiences, evaluating well-established and emerging unmet therapeutic opportunities, solving clinical problems, and clarifying best practices. This year’s offering will again feature the dynamic and interactive Medical Crossfire® discussion panels, allowing for exploration of some of the most challenging topics for which there may exist potential approaches to care. As a result of this exploration, participants will leave the Miami Lung Cancer Conference® with a higher level of comprehension than they would otherwise have achieved.
Target AudienceThis educational activity is directed toward oncologists involved in the treatment and management of patients with lung cancers. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment of lung cancers may also participate.
At the conclusion of this symposium, you should be better prepared to:
- Discuss evidence-based recommendations regarding tumor tissue testing and its role in therapeutic selection for the patients with NSCLC
- Assess clinical decision-making necessary along multiple lines of care concerning the use of chemotherapeutic, targeted, and immunooncology strategies in the setting of NSCLC
- Discuss evolving data sets on immunooncology strategies and their use in lung cancers
- Describe the role of cytotoxic and antiangiogenic approaches in the management of advanced NSCLC
- Explain optimized strategies to target oncogenic drivers in frontline settings and beyond disease progression
- Describe advances and future directions for care in the management of squamous NSCLC, as well as treatment considerations for special populations of patients with lung cancer
- Integrate personalized approaches to manage challenging cases and real-world clinical scenarios in advanced lung cancer settings
Program ChairHeather A. Wakelee, MD
Associate Professor, Medicine (Oncology)
Stanford University Medical Center